CUE Cue Biopharma

P/E --
Forward P/E --
Price/Sales 4.748
Beta 2.628
Div Yield --
Market Cap --

Company Analysis

Latest News

πŸ”΄ Cue Biopharma is trading 5% down today after Purcell & Lefkowitz announced shareholder investigation

Cue Biopharma is trading at $22.77 (-5.05%) after Purcell & Lefkowitz announced a shareholder investigation into recent corporate actions. - Wall Street Zen...

Cue Biopharma Downgraded to Sell, Following Massive $24.14 Per Share Loss

Cue Biopharma Downgraded to Sell, Following Massive $24.14 Per Share Loss

Wall Street Zen downgraded Cue Biopharma (NASDAQ:CUE) from hold to sell on Sunday. This action contributes to a consensus sell rating for the company. The...

πŸ”΄ Cue Biopharma is trading 5.2% down today

Cue Biopharma is trading 5.2% down at $23.32 after reversing an early pre-market rebound. - No clear company-specific announcement was identified for August...

🟒 Cue Biopharma is trading 5.57% up in pre-market amid broader risk-on rebound

Cue Biopharma is trading 5.57% up in pre-market at $25.98, appearing to reflect broader pre-market risk appetite after the previous session’s selloff. -...

πŸ”΄ Cue Biopharma falls 5.0% β€” Biotech Sector Cools Off After Moderna-Sparked Rally

With Biotech (XBI) down 2.5%, this looks like a sector-led move rather than a company-specific surprise. The biotech sector is experiencing a pullback after a...

🟒 Cue Biopharma is trading 6.9% up today amid continued reaction to Q2 results

Cue Biopharma is trading 6.9% up at $28.08, continuing a volatile reaction to its August 14, 2026 second-quarter results and recent pipeline developments. -...

🟒 Cue Biopharma is trading 5% up in after-hours trading after earnings and a two-session slide

Cue Biopharma is trading 5.06% up in after-hours trading at $27.00, appearing to reflect continued post-earnings volatility and a rebound after two consecutive...

πŸ”΄ Cue Biopharma is trading 10% down today after senior executives sold substantial shareholdings

Cue Biopharma is trading 9.99% down at $24.88 after an August 18 disclosure that senior executives sold substantial shareholdings. - The legal chief sold...

Cue Biopharma's $153 Million Loss Dwarfs Revenue Gains β€” Can One-Time Charges Excuse the Sticker Shock?

Cue Biopharma's $153 Million Loss Dwarfs Revenue Gains β€” Can One-Time Charges Excuse the Sticker Shock?

Shares of Cue Biopharma plunged 13.7% to $29.53 as investors digested a second-quarter loss so large it made the company's genuine revenue progress almost...

πŸ”΄ Cue Biopharma is trading 13.65% down today after Q2 net loss rose to $153.1 million

Cue Biopharma is trading at $29.53, down -13.65% after August 14, 2026, Q2 earnings showed a $153.1 million net loss, versus $8.5 million a year earlier. -...

πŸ”΄ Cue Biopharma is trading 6.1% down today after second-quarter net loss widened to $153.1 million

Cue Biopharma is trading 6.1% down at $32.12 after investors reassessed its August 14 second-quarter results. - Revenue rose to $7.9 million from $3.0...

Cue Biopharma Q2 2026 Earnings Preview: What Analysts Expect on August 18, 2026

Analyst consensus points to Q2 revenue of $3.00 million and an EPS loss of -$1.69, while the stock currently trades at $34.20, significantly below the average...

Cue Biopharma Downgraded to Hold, Following $1.6 Million CEO Stock Sale

Cue Biopharma Downgraded to Hold, Following $1.6 Million CEO Stock Sale

Wall Street Zen downgraded Cue Biopharma (NASDAQ:CUE) from buy to hold on Saturday. The action follows the company’s August 14 second-quarter earnings report....

Cue Biopharma second quarter 2026 revenue hits $7.9M as CUE-221 acquisition expenses drive losses

Cue Biopharma second quarter 2026 revenue hits $7.9M as CUE-221 acquisition expenses drive losses

Cue Biopharma reported second quarter 2026 collaboration revenue of $7.9 million, up from $3.0 million year-over-year, driven by milestones from its Boehringer...

πŸ”΄ Cue Biopharma is trading 6.73% down in after-hours trading as immediate catalyst remains unclear

Cue Biopharma is trading 6.73% down at $31.90 after closing at $34.20 on August 14, 2026; the immediate catalyst remains unclear. - No confirmed...

🟒 Cue Biopharma is trading 11.33% up today with no confirmed catalyst

Cue Biopharma is trading 11.33% up at $34.60, with the cause unclear. - Gains extended from August 11 through August 13; no verified company-specific...

🟒 Cue Biopharma is trading 5.86% up today with no verified company-specific catalyst

Cue Biopharma is trading 5.86% up at $32.90, with no verified company-specific announcement dated August 14, 2026 identified. - The latest official company...

🟒 Cue Biopharma is trading 6% up today as flat July PPI eased rate-hike concerns

Cue Biopharma is trading 5.95% up at $32.23, likely supported by broader risk-on sentiment after flat July PPI eased rate-hike concerns. - No verified...

πŸ”΄ Cue Biopharma is trading 10.47% down today with no clear catalyst

Cue Biopharma is trading at $27.23 (-10.47%) after no verified company-specific announcement was identified for August 13, 2026. β€’ The latest official...

πŸ”΄ Cue Biopharma is trading 6.25% down today with no verified company-specific announcement identified

Cue Biopharma is trading 6.25% down at $28.52 after no verified company-specific announcement was identified for August 13, 2026. - The latest official...